Skip to main content
Download PDF

Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients

Radiation Oncology volume 15, Article number: 29 (2020) Cite this article

The Original Article was published on 25 October 2019

Correction to: Radiat Oncol

https://doi.org/10.1186/s13014-019-1375-0

Following publication of the original article [1], we have been notified that the below text parts of the Discussion chapter should be changed. Currently the text is as follows:

Discussion

The influence of the Bragg peak degradation due to lung tissue on treatment plans of lung cancer patients was investigated. For all cases the treatment-planning system overestimated the dose delivered to the CTV and in some cases underestimated the dose delivered to distal OARs. This effect increases with an increasing modulation power. The maximum underestimation of the mean dose Dmean is − 5% for the CTV and an extreme modulation power of 800 μm. The average underestimation is in the order − 2%. This extreme modulation power of 800 μm can occur in cases where a larger bronchial structure in the lung is positioned in the proton beam. However, for a more realistic modulation power of 450 μm, the underestimation of the mean dose Dmean is only about − 3% at maximum. The average underestimation is roughly − 1%.

Altogether, the effects of the Bragg peak degradation are at maximum about 5% concerning the underestimation of the mean dose Dmean in the CTV when optimizing the treatment plan without considering the degradation due to the lung tissue.

The above-mentioned text should be corrected as per below:

Discussion

The influence of the Bragg peak degradation due to lung tissue on treatment plans of lung cancer patients was investigated. For all cases the treatment-planning system overestimated the dose delivered to the CTV and in some cases underestimated the dose delivered to distal OARs. This effect increases with an increasing modulation power. The maximum overestimation of the mean dose Dmean is 5% for the CTV and an extreme modulation power of 800 μm. The average overestimation is in the order 2%. This extreme modulation power of 800 μm can occur in cases where a larger bronchial structure in the lung is positioned in the proton beam. However, for a more realistic modulation power of 450 μm, the overestimation of the mean dose Dmean is only about 3% at maximum. The average overestimation is roughly 1%.

Altogether, the effects of the Bragg peak degradation are at maximum about 5% concerning the overestimation of the mean dose Dmean in the CTV when optimizing the treatment plan without considering the degradation due to the lung tissue.

Reference

  1. Baumann, et al. Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients. Radiat Oncol. 2019;14:183. https://doi.org/10.1186/s13014-019-1375-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medical Center Giessen-Marburg, Department of Radiotherapy and Radiooncology, Marburg, Germany

    Kilian-Simon Baumann, Veronika Flatten, Stefan Lautenschläger, Fabian Eberle, Klemens Zink & Rita Engenhart-Cabillic

  2. University of Applied Sciences, Institute of Medical Physics and Radiation Protection, Giessen, Germany

    Kilian-Simon Baumann, Veronika Flatten & Klemens Zink

  3. GSI Helmholtzzentrum für Schwerionenforschung, Biophysics Division, Darmstadt, Germany

    Uli Weber

  4. Marburg Ion-Beam Therapy Center (MIT), Marburg, Germany

    Stefan Lautenschläger, Fabian Eberle & Rita Engenhart-Cabillic

  5. Frankfurt Institute of Advanced Studies – FIAS, Frankfurt, Germany

    Klemens Zink

Authors
  1. Kilian-Simon Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veronika Flatten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uli Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Lautenschläger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabian Eberle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Klemens Zink
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rita Engenhart-Cabillic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kilian-Simon Baumann.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baumann, KS., Flatten, V., Weber, U. et al. Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients. Radiat Oncol 15, 29 (2020). https://doi.org/10.1186/s13014-020-1475-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13014-020-1475-x

Radiation Oncology

ISSN: 1748-717X

Contact us